Lipella Pharmaceuticals Common Stock Net Income
| LIPO Stock | 3.19 0.06 1.92% |
Lipella Pharmaceuticals Common fundamentals help investors to digest information that contributes to Lipella Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lipella Stock. The fundamental analysis module provides a way to measure Lipella Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lipella Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -2.3 M | -2.2 M | |
| Net Loss | -4.2 M | -3.9 M | |
| Net Loss | -3.9 M | -3.7 M | |
| Net Loss | (7.08) | (6.72) | |
| Net Income Per E B T | 1.15 | 1.13 |
Lipella | Net Income |
Lipella Pharmaceuticals Common Company Net Income Analysis
Lipella Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Lipella Pharmaceuticals Net Income | (4.62 M) |
Most of Lipella Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipella Pharmaceuticals Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Lipella Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lipella Pharmaceuticals is extremely important. It helps to project a fair market value of Lipella Stock properly, considering its historical fundamentals such as Net Income. Since Lipella Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lipella Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lipella Pharmaceuticals' interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lipella Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lipella Pharmaceuticals Common reported net income of (4.62 Million). This is 101.35% lower than that of the Biotechnology sector and 106.59% lower than that of the Health Care industry. The net income for all United States stocks is 100.81% higher than that of the company.
Lipella Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipella Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipella Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lipella Pharmaceuticals by comparing valuation metrics of similar companies.Lipella Pharmaceuticals is currently under evaluation in net income category among its peers.
Lipella Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lipella Pharmaceuticals from analyzing Lipella Pharmaceuticals' financial statements. These drivers represent accounts that assess Lipella Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lipella Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Enterprise Value | 32.5M | 31.9M | 139.1M | 3.0M | 2.7M | 2.5M |
Lipella Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lipella Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lipella Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Lipella Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Lipella Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lipella Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lipella Pharmaceuticals' value.| Shares | Virtu Financial Llc | 2024-12-31 | 13.3 K | Mccormack Advisors International | 2024-12-31 | 125 | Bank Of America Corp | 2024-12-31 | 7.0 | Sabby Management Llc | 2024-09-30 | 0.0 | Two Sigma Investments Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 |
Lipella Fundamentals
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.94 | ||||
| Operating Margin | (6.98) % | ||||
| Current Valuation | 2.57 M | ||||
| Shares Outstanding | 1.21 M | ||||
| Shares Owned By Insiders | 29.37 % | ||||
| Shares Owned By Institutions | 6.51 % | ||||
| Number Of Shares Shorted | 30.82 K | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 7.98 X | ||||
| Revenue | 449.62 K | ||||
| Gross Profit | (2.36 M) | ||||
| EBITDA | (4.61 M) | ||||
| Net Income | (4.62 M) | ||||
| Total Debt | 136.59 K | ||||
| Book Value Per Share | 1.79 X | ||||
| Cash Flow From Operations | (3.15 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (4.88) X | ||||
| Target Price | 16.0 | ||||
| Market Capitalization | 3.57 M | ||||
| Total Asset | 3.58 M | ||||
| Retained Earnings | (10.32 M) | ||||
| Working Capital | 3.04 M | ||||
| Net Asset | 3.58 M |
About Lipella Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipella Pharmaceuticals Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipella Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipella Pharmaceuticals Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lipella Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipella Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipella Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Lipella Stock
The ability to find closely correlated positions to Lipella Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipella Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipella Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipella Pharmaceuticals Common to buy it.
The correlation of Lipella Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipella Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipella Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipella Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Lipella Pharmaceuticals Piotroski F Score and Lipella Pharmaceuticals Altman Z Score analysis. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipella Pharmaceuticals. If investors know Lipella will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipella Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.88) | Revenue Per Share | Quarterly Revenue Growth 0.279 | Return On Assets | Return On Equity |
The market value of Lipella Pharmaceuticals is measured differently than its book value, which is the value of Lipella that is recorded on the company's balance sheet. Investors also form their own opinion of Lipella Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Lipella Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipella Pharmaceuticals' market value can be influenced by many factors that don't directly affect Lipella Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipella Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipella Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipella Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.